SlideShare a Scribd company logo
1 of 106
Download to read offline
ASRA GUIDELINES
4th Edition, April 2018
( 3RD Edition, Jan 2010 )
Dr Krunal Bhatt
Anesthesiology and Critical Care
AFMC, Pune
• 1st consensus conference : 1997
• 2nd consensus conference : 2002
No Change
LEVEL OF EVIDENCE
• A : RCT and Meta Analysis
• B : Observational and Epidemiological Series
• C : Case Reports or Expert Opinion
No Change
GRADE OF RECOMMENDATION
• 1 : General Agreement in the efficacy
• 2 : Conflicting Evidence or opinion on usefulness
• 3 : May not be useful
• We recommend : grades 1A,1B,1C
• We suggest : grades 2A,2B,2C
No Change
CONCERNS
1. Administration of thromboprophylaxis
2. Anesthetic Mx of pt receiving Thrombolytic Therapy
3. Anesthetic Mx of pt receiving UFH
4. Anesthetic Mx of pt receiving LMWH
5. Anesthetic Mx of pt receiving Fondaparinaux
6. Anesthetic Mx of pt receiving Rivaroxaban
7. Anesthetic Mx of pt receiving Apixaban
8. Anesthetic Mx of pt receiving Edoxaban
9. Anesthetic Mx of pt receiving Betrixaban
10. Anesthetic Mx of pt receiving Direct Thrombin Inhibitors
11. Anesthetic Mx of pt receiving Dabigatran
12. Regional Anesthetic Mx of pt receiving Warfarin
13. Anesthetic Mx of pt receiving Antiplatelet Medications
14. Anesthetic Mx of pt receiving Herbal Therapy
15. Anesthetic Mx of the Anticoagulated Parturient
16. Anesthetic Mx of pt receiving undergoing Plexus or
Peripheral Block
VTE
RISK FACTORS FOR VTE
Surgery Trauma Immobility
Cancer and its treatment Venous compression H/o VTE
Increasing age Acute medical illness Estrogen pills/HRT
Inherited/Acquired
Thrombophilia
Erythropoiesis modulating
agents
Pregnancy and Post
partum period
IBDz Nephrotic syndrome Myeloproliferative dz
PNH Obesity CVC
SERM
1. Administration of THROMBOPROPHYLAXIS
1. For each of the antithrombotic agents, we recommend that
clinicians follow FDA approved dosing and ACCP Mx
guidelines ( grade 1A )
No Change
2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY
1. In patients scheduled to receive thrombolytic therapy, we
recommend that the pt be queried and medical record
reviewed for a recent history of lumbar puncture, spinal or
epidural anesthesia, or ESI to allow appropriate monitoring
guidelines detailing original contraindications to
thrombolytic drugs suggest avoidance of these drugs for 10
days following puncture of non compressible vessels
( grade 1A )
No Change
2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY
2. In patients who have received fibrinolytic and thrombolytic
drugs, we recommend against performance of spinal or
epidural anesthetics except in highly unusual circumstances
( grade 1A )
No Change
2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY
3. Data are not available to clearly outline the length of time
neuraxial puncture should be avoided after discontinuation
of these drugs. However, a 48 hr time interval and
documentation of normalization of clotting studies (
including fibrinogen ) are suggested ( grade 2C )
No Change
2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY
4. In those patients who have received neuraxial blocks at or
near the time of fibrinolytic and thrombolytic therapy, we
recommend that neurological monitoring should be
continued for an appropriate interval. It may be that the
interval of monitoring should not be more than 2 hrs
between neurological checks. If neuraxial blocks have been
combined with fibrinolytic and thrombolytic therapy and
ongoing epidural catheter infusion, we recommend the
infusion should be limited to drugs minimizing sensory and
motor block to facilitate assessment of neurologic function
( grade 1C )
No Change
2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY
5. There is no definitive recommendation for removal of
neuraxial catheters in pts who unexpectedly receive
fibrinolytic and thrombolytic therapy during a neuraxial
catheter infusion. We suggest the measurement of
fibrinogen level ( one of that last clotting factors to recover )
to evaluate the presence of residual thrombolytic effect and
appropriate timing of catheter removal ( grade 2C )
No Change
IV and SC UFH
3. Anesthetic Mx of pt receiving UFH
1. We recommend daily review of the pt’s medical record to
determine the concurrent use of medications that affect
other components of the clotting mechanisms. These
medications include antiplatelet medications, LMWH, and
oral anticoagulants ( grade 1B )
No Change
3. Anesthetic Mx of pt receiving UFH
2. Since HIT may occur during heparin administration, we
recommend that pt receiving IV or SC UFH for more than 4
days have a platelet count assessed prior to neuraxial block
or catheter removal ( grade 1C )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
1. Discontinue heparin infusion 4 to 6 hrs and verify normal
coagulation status prior to neuraxial blockade ( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
2. Avoid neruaxial techniques in pts with other
coagulopathies ( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
3. Delay heparin administration for 1 hr after needle
placement ( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
4. Remove indwelling neuraxial catheters 4 to 6 hrs after the
last heparin dose ( and after assessment of the pt’s
coagualtion status ) ; reheparinize 1 hr after catheter
removal ( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
5. Monitor pt postoperatively to provide early detection of
motor blockade and consider use of minimal concentration
of LAs to enhance early detection of spinal hematoma
( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
6. Although the occurrence of bloody or difficult neuraxial
needle placement may increase risk, there are no data to
support mandatory cancellation of a case. Direct
communication with the surgeon and a specific risk benefit
decision about proceeding in each case are warranted
( grade 1A )
No Change
3. Anesthetic Mx of pt receiving UFH
3. Intravenous Heparin
7. Currently, insufficient data and experience are available to
determine if the risk of neuraxial hematoma is increased
when combining neuraxial techniques with the full
anticoagulation of cardiac surgery. We suggest postop
monitoring of neurologic function and selection of neuraxial
solutions that minimize sensory and motor block to facilitate
detection of new/progressive neurodeficits ( grade 2C )
No Change
3. Anesthetic Mx of pt receiving UFH
4. Subcutaneous Heparin
1. Preop low dose UFH for thromboprophylaxis. We suggest,
in pts receiving SC low dose UFH with dosing regimens of
5000 IU BID/TID, neuraxial block occur 4 to 6 hrs after
heparin administration, or coagulation status be assessed
( grade 2C )
No Change
3. Anesthetic Mx of pt receiving UFH
4. Subcutaneous Heparin
2. Preop “higher dose” UFH for thromboprophylaxis (eg.
Individual heparin dose of 7500-10000 IU BID or daily dose
of ≤ 20000 IU ). We suggest, neuraxial block occur 12 hrs
after SC heparin administration and assessment of
coagulation status
( grade 2C )
No Change
3. Anesthetic Mx of pt receiving UFH
4. Subcutaneous Heparin
3. Preop therapeutic UFH ( eg. Individual dose > 10000 IU SC
per dose or > 20000 IU total daily dose ). We suggest
neuraxial block occure 24 hrs after SC heparin administration
and assessment of coagulation status ( grade 2C )
No Change
3. Anesthetic Mx of pt receiving UFH
4. Subcutaneous Heparin
4. Postop low dose UFH. There is no contraindication to
maintaining neuraxial catheters in the presence of low dose
UFH. We suggest catheter removal occur 4 to 6 hrs after
heparin administration. Subsequent heparin administration
may occur 1 hr after catheter removal ( grade 2C )
No Change
3. Anesthetic Mx of pt receiving UFH
4. Subcutaneous Heparin
5. Postop “Higher dose” UFH. The safety of indwelling
neuraxial catheters in pts receiving doses > 5000 IU or >
15000 IU of UFH daily has not been established. We suggest
that the risk and benefits be assessed on an individual basis
and that techniques to facilitate detection of
new/progressive neurodefits ( eg. Enhanced neuro
monitoring occur and neuraxial solutions to minimize
sensory and motor block ) be applied ( grade 2C )
No Change
LMWH
4. Anesthetic Mx of pt receiving LMWH
1. The anti-factor Xa level is not predictive of the risk of
bleeding, although it may be useful in monitoring efficacy of
therapy with therapeutic ( high dose ) regimens. We
recommend against the routine use of monitoring of anti-
factor Xa level. An acceptable level of residual anti-factor Xa
level for performance of neuraxial block remains
undetermined ( grade 1A )
The increased availability of anti-factorXa activity level allows for preop assessment of residual
anticoagualant effect in pt on higher dose LMWH
4. Anesthetic Mx of pt receiving LMWH
2. Antiplatelet or oral anticoagulant medications administered
in combination with LMWH increase the risk of spinal
hematoma. Education of entire pt care team is necessary to
avoid potentiation of the anticoagualnt effects. We
recommend against concomitant administration of
medications affecting hemostatsis, such as antiplatelet
drugs, standard heparin or dextran, regardless of LMWH
dosing regimen when there is an indwelling neuraxial
catheter ( grade 1A )
No Change
4. Anesthetic Mx of pt receiving LMWH
3. Since HIT may occur during LMWH administration, We
recommend that pts receiving LMWH for greater than 4 days
have a platelet count assessed prior to neuraxial block or
catheter removal ( grade 1C )
No Change
4. Anesthetic Mx of pt receiving LMWH
4. The presence of blood during needle and catheter placement
does not necessitate postponement of surgery. We suggest
that initiation of LMWH therapy in this setting should be
delayed for 24 hrs postop and that this consideration be
discussed with the surgeon ( grade 2C )
No Change
4. Anesthetic Mx of pt receiving LMWH
5. Preop LMWH
1. We recommend that needle placement should occur at
least 12 hrs after prophylactic LMWH dose ( grade 1C )
No Change
4. Anesthetic Mx of pt receiving LMWH
5. Preop LMWH
2. In pts administered a dose of LMWH 2 hrs preoperatively
(general surgery pts), we recommend against neuraxial
techniques because needle placement would occur close to
peak anticoagulant activity ( grade 1A )
No Change
4. Anesthetic Mx of pt receiving LMWH
5. Preop LMWH
3. In pts receiving higher (therapeutic) LMWH (eg.
Enoxaparin 1mg/kg 12hrly or 1.5mg/kg daily, Dalteparin
120U/kg 12hrly or 200U/kg daily, Tinzaparin 175U/kg daily),
We recommend delay of ≥24hrs to needle/catheter
placement (grade 1C). Consider checking anti-factorXa
activity, particularly in elderly pts and with renal
insufficiency. Acceptable level of residual anti-factorXa
activity to proceed with neuraxial block remains
undetermined (grade 2C)
Residual anti-factorXa activity may be present even after 24hrs. Assessment, especially in pt with mod
to severe renal insufficiency, may be considered.
4. Anesthetic Mx of pt receiving LMWH
6. Postop LMWH
1. BID prophylatic dose, associated with increased risk of
spinal hematoma. We recommend 1st dose LMWH should be
administered following day and no earlier than 12hrs after
needle/catheter placement, regardless of anesthetic
technique, & only in presence of adequate (surgical)
hemostasis. Indwelling catheters be removed prior to
initiation of LMWH thromboprophylaxis. Administration of
LMWH be delayed for 4hr after catheter removal ( grade 1C )
Previously recommeded was a 1st dose 24hr after needle/catheter placement and delay of LMWH
dosing for only 2hr after catheter removal. These recommendations incorporate labelling changes
made by FDA.
4. Anesthetic Mx of pt receiving LMWH
6. Postop LMWH
2. OD prophylatic dose. We recommend 1st dose LMWH
should be administered ≥12hrs after needle/catheter
placement. The 2nd postop dose should occur >24hrs after 1st
dose. Indwelling catheters don't represent increased risk and
may be maintained. No additional hemostasis altering drugs
be administered because of additive effects. Catheter
removed 12hr last dose LMWH. Subsequent LMWH ≥4hrs
after catheter removal ( grade 1C )
Previously recommended was 10-12hrs for both needle/catheter placement and catheter removal.
Subsequent LMWH 2hrs after catheter removal. These recommendations incorporate labeling changes
made by FDA.
4. Anesthetic Mx of pt receiving LMWH
6. Postop LMWH
3. OD/BD Therapeutic dose. Therapeutic dose LMWH may be
resumed 24 after non-high-bleeding-risk surgery and 48 to
72 hrs after high-bleeding-risk surgery. We recommend that
indwelling neuraxial catheter be removed 4 hrs prior to 1st
postop dose and ≥ 24 hrs after needle/catheter placement,
whichever is greater ( grade 1C )
No Change
ANTI – FACTOR Xa AGENTS
• Fondaparinux
5. Anesthetic Mx of pt receiving FONDAPARINAUX
1. Based on the sustained and irreversible antithrombotic
effect, early postop dosing and the spinal hematoma
reported during initial clinical trials, we recommend that
until further clinical experience is available performance of
neuraxial techniques should occur under conditions used in
clinical trials ( single needle pass, atraumatic needle
placement, avoidance of indwelling neuraxial catheters ). If
this is not feasible, an alternate method of prophylaxis
should be considered ( grade 1C )
No Change
5. Anesthetic Mx of pt receiving FONDAPARINAUX
2. We suggest that neuraxial catheters 6 hrs be removed prior
to 1st postop dose ( grade 2C )
No Change
NEW DIRECT ORAL ANTI-FACTOR Xa
AGENTS
• Rivaroxaban
• Apixaban
• Edoxaban
• Betrixaban
6. Anesthetic Mx of pt receiving RIVAROXABAN
1. We suggest that rivaroxaban be discontinued 72 hrs prior to
neuraxial block. Consider checking rivaroxaban or anti-factor
Xa activity level if less than 72 hrs. An acceptable level of
residual rivaroxaban activity to proceed with neuraxial block
remains undetermined ( grade 2C )
NEW
6. Anesthetic Mx of pt receiving RIVAROXABAN
2. We suggest that neuraxial catheters be removed 6 hrs prior
to the 1st postop dose ( grade 2C )
NEW
6. Anesthetic Mx of pt receiving RIVAROXABAN
3. With unanticipated administration with indwelling catheter,
we suggest that rivaroxaban dosing be held for 22 to 26 hrs
before or an anti-factor Xa assay calibrated to rivaroxaban be
assessed before catheter is removed ( grade 2C )
NEW
7. Anesthetic Mx of pt receiving APIXABAN
1. We suggest that Apixaban be discontinued 72 hrs prior to
neuraxial block. Consider checking Apixaban or anti-factor Xa
activity level if less than 72 hrs. An acceptable level of
residual Apixaban activity to proceed with neuraxial block
remains undetermined ( grade 2C )
NEW
7. Anesthetic Mx of pt receiving APIXABAN
2. We suggest that neuraxial catheters be removed 6 hrs prior
to the 1st postop dose ( grade 2C )
NEW
7. Anesthetic Mx of pt receiving APIXABAN
3. With unanticipated administration with indwelling catheter,
we suggest that Apixaban dosing be held for 26 to 30 hrs
before or an anti-factor Xa assay calibrated to Apixaban be
assessed before catheter is removed ( grade 2C )
NEW
8. Anesthetic Mx of pt receiving EDOXABAN
1. We suggest that Edoxaban be discontinued 72 hrs prior to
neuraxial block. Consider checking Edoxaban or anti-factor
Xa activity level if less than 72 hrs. An acceptable level of
residual Edoxaban activity to proceed with neuraxial block
remains undetermined ( grade 2C )
NEW
8. Anesthetic Mx of pt receiving EDOXABAN
2. We suggest that neuraxial catheters be removed 6 hrs prior
to the 1st postop dose ( grade 2C )
NEW
8. Anesthetic Mx of pt receiving EDOXABAN
3. With unanticipated administration with indwelling catheter,
we suggest that Edoxaban dosing be held for 20 to 28 hrs
before or an anti-factor Xa assay calibrated to Edoxaban be
assessed before catheter is removed ( grade 2C )
NEW
9. Anesthetic Mx of pt receiving BETRIXABAN
1. We suggest that Betrixaban be discontinued a minimum of 3
days prior to neuroaxial block. Consider checking Betrixaban
or anti-factor Xa activity level if less than 3 days ( grade 2C )
NEW
9. Anesthetic Mx of pt receiving BETRIXABAN
2. We suggest against the performance of neuraxial blocks in pt
with a CrCL < 30ml/min ( grade 2C )
NEW
9. Anesthetic Mx of pt receiving BETRIXABAN
3. We suggest that neuraxial catheters 5 hrs be removed prior
to next dose ( grade 2C )
NEW
9. Anesthetic Mx of pt receiving BETRIXABAN
4. With unanticipated administration with indwelling catheter,
we suggest that Betrixaban dosing be held for 72 hrs, than
the catheter removed ( grade 2C )
NEW
DIRECT THROMBIN INHIBITORS
• Desirudin
• Bivalirudin
• Argatroban
10. Anesthetic Mx of pt receiving Parenteral DTI
1. In pt receiving parenteral thrombin inhibitors, we
recommend against the performance of neuraxial
techniques ( grade 2C )
No Change
ORAL THROMBIN INHIBITORS
• Dabigatran
11. Anesthetic Mx of pt receiving DABIGATRAN
1. We suggest that Dabigatran be discontinued 120 hrs prior to
neuraxial block. However, if renal function has been reliably
determined, and there are no additional risk factors for
bleeding ( eg. Age>65yrs, hypertension, concomitant
antiplatelet medications ) , a more graded approach may be
considered
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
1. We suggest that Dabigatran be discontinued 120 hrs prior to
neuraxial block. However, if renal function has been reliably
determined, and there are no additional risk factors for
bleeding ( eg. Age>65yrs, hypertension, concomitant
antiplatelet medications ) , a more graded approach may be
considered
1. We suggest dabigatran be discontinued 72hrs in pt with
CrCL ≥80ml/min. Consider checking dTT or ECT if <72hrs.
Acceptable level of residual dabigatran activity to proceed
with neuraxial block remains undetermined ( grade 2C )
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
1. We suggest that Dabigatran be discontinued 120 hrs prior to
neuraxial block. However, if renal function has been reliably
determined, and there are no additional risk factors for
bleeding ( eg. Age>65yrs, hypertension, concomitant
antiplatelet medications ) , a more graded approach may be
considered
2. We suggest dabigatran be discontinued 96hrs in pt with
CrCL 50-79ml/min. Consider checking dTT or ECT if <96hrs.
Acceptable level of residual dabigatran activity to proceed
with neuraxial block remains undetermined ( grade 2C )
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
1. We suggest that Dabigatran be discontinued 120 hrs prior to
neuraxial block. However, if renal function has been reliably
determined, and there are no additional risk factors for
bleeding ( eg. Age>65yrs, hypertension, concomitant
antiplatelet medications ) , a more graded approach may be
considered
3. We suggest dabigatran be discontinued 120hrs in pt with
CrCL 30-49ml/min. Consider checking dTT or ECT if <120hrs.
Acceptable level of residual dabigatran activity to proceed
with neuraxial block remains undetermined ( grade 2C )
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
1. We suggest that Dabigatran be discontinued 120 hrs prior to
neuraxial block. However, if renal function has been reliably
determined, and there are no additional risk factors for
bleeding ( eg. Age>65yrs, hypertension, concomitant
antiplatelet medications ) , a more graded approach may be
considered
4. We suggest against the performance of neuraxial blocks in
pts with CrCL <30ml/min ( grade 2C )
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
2. We suggest that neuraxial catheters be removed 6 hrs prior
to the 1st postop dose ( grade 2C )
NEW
11. Anesthetic Mx of pt receiving DABIGATRAN
3. With unanticipated administration with indwelling catheter,
we suggest that dabigatran dosing be held for 34 to 36 hrs
before or dTT or ECT assessed before the catheter is
removed ( grade 2C )
NEW
12. Regional Anesthetic Management of pt on WARFARIN
1. Caution should be used when performing neuraxial tech in
pts recently discontinued from chronic warfarin therapy. In
first 1-3 days after discontinuation of warfarin therapy,
coagulation status (reflected primarily by factor II and X
levels) may not be adequate for hemostasis despite a
decrease in INR (Indicating return of factor VII activity).
Adequate levels of factor II,VII,IX and X may not be present
until INR is within normal limits. We recommend the
anticoagulant therapy must be stopped (Ideally 5 days prior
to planned procedure), and the INR normalized prior to
initiation of neuraxial block ( grade 1B )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
2. We recommend against the concurrent use of medications
that affect other component of the clotting mechanisms and
may increase the risk of bleeding complications for patients
receiving oral anticoagulants and do so without influencing
the INR. These medications include aspirin and other
NSAIDs, thienopyridines, UFH and LMWH ( grade 1A )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
3. In pt who are likely to have an enhanced response to drug,
we recommend that reduced dose be administered
( grade 1B )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
4. In pts receiving an initial dose of warfarin prior to surgery, we
suggest INR should be checked prior to neuraxial block if the
first dose was given > 24hrs earlier or a second dose of oral
anticoagulant has been administered ( grade 2C )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
5. In pts receiving low dose of warfarin therapy during epidural
analgesia, we suggest that their INR be monitored on a daily
basis ( grade 2C )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
6. Neurological monitoring of sensory and motor function
should be performed routinely during epidural analgesia for
pt on warfarin therapy. To facilitate , we recommend that the
type of analgesic solution be tailored to minimize degree of
sensory and motor blockade ( grade 1C )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
7. As thromboprophylaxis with warfarin is initiated, we suggest
that neuraxial catheters be removed when the INR <1.5.
While removal of epidural catheters 12-24hrs after warfarin
was given does not appear to represent increase risk, the
risk of removing epidural catheter at 48hrs is not
guaranteed.
This is a new recommendation based on recent lab studies assessing factor levels and INR as well as
clinical studies in pts receiving wararin during epidural catheterization
12. Regional Anesthetic Management of pt on WARFARIN
8. In pt with INR >1.5 but <3, the increase in risk with
progressive INR prolongation remains unknown. We suggest
indwelling catheters may be maintained with caution, based
on INR and duration of warfarin therapy ( grade 2C )
This is a new recommendation based on recent lab studies assessing factor levels and INR as well as
clinical studies in pts receiving wararin during epidural catheterization
12. Regional Anesthetic Management of pt on WARFARIN
9. In pt with INR >3 , we recommend that the warfarin dose be
held or reduced in pts with indwelling neuraxial catheters
( grade1A )
We can make no definitive recommendation regarding the
management to facilitate removal of neuraxial catheters in
pt with therapeutic levels of anticoagulation during neuraxial
catheter infusion ( grade 2C )
No Change
12. Regional Anesthetic Management of pt on WARFARIN
10. We suggest that neurological assessment be continued for at
least 24 hrs following catheter removal ( grade 2C )
No Change
ANTIPLATELET MEDICATIONS
• NSAIDs
• Thienopyridines
• Ticagrelor
• Cangrelor
• Pl GPIIb/IIIa Receptor Antagonists
• Cilastazol
• Dipyridamol
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
1. NSAIDs
1. NSAIDs appear to represent no added significant risk of
development of spinal hematoma in pt having epidural or
spinal anesthesia. NSAIDs ( including Aspirin ) do not create
a level of risk that will interfere with the performance of
neuraxial blocks. In pts receiving these medications, we do
not identify specific concerns as to the timing of single
injection or catheter techniques in relationship to the dosing
of NSAIDs, postop monitoring, or the timing of neuraxial
catheter removal ( grade 1A )
No Change
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
1. NSAIDs
2. In pts receiving NSAIDs, we suggest caution in the
performance of neuraxial techniques if the concurrent use of
other medications affecting clotting mechanisms, such as
other (nonNSAIDs) antiplatelet agents, oral anticoagulants,
UFH & LMWH is anticipated in early postop period because
of increase risk of bleeding complications. COX2 inhibitors
have minimal effect on platelet function and should be
considered in pt who require anti-inflammatory therapy in
presence of anticoagulation ( grade 2C )
No Change
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
2. Thienopyridines
1. Preop : Based on labelling and surgical/procedural
experience, the recommended time interval between
discontinuation of thienopyridine therapy and neuraxial
blockade is 10 days for ticlopidine, 5-7 days for clopidogrel,
and 7-10 days for prasugrel ( grade 1C )
Previous time intervals were 14days for ticlopidine and 7 days for clopidogrel. The new time intervals
reflect ACCP recommendations. The prasugrel recommendation is new.
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
2. Thienopyridines
2. Postop : In accordance with ACCP recommendations,
thienopyridine therapy may be reinstituted 24 hrs
postoperatively ( grade 1A )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
2. Thienopyridines
3. Neuraxial catheters should not be maintained with
prasugrel or ticagrelor because of rapid onset. However,
because the antiplatelet effect is not immediate with
ticlopidine and clopidogrel, neuraxial catheters may be
maintained for 1-2 days, provided a loading dose of the
antiplatelet agent is not administered. ( grade 1A )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
2. Thienopyridines
4. Thienopyridine therapy may be resumed immediately
after needle placement/catheter removal, provided a
loading dose of the drugs is not administered. If a loading
dose is administered, we suggest a time interval of 6 hrs
between catheter removal and administration ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
3.
ASRA SOCIETY FORGET TO MENTION THIS POINT. I HAVE MAILED
THEM REGARDING THIS.
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
4. Ticagrelor
1. Preop : Based on labeling and surgical/procedural
experience, the recommended time interval between
discontinuation of ticagrelor therapy and neuraxial blockade
is 5-7 days ( grade 1C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
4. Ticagrelor
2. Postop : In accordance with ACCP recommendations,
ticagrelor therapy may be reinstituted 24 hrs postoperatively
( grade 1A )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
4. Ticagrelor
3. Neuraxial catheters should not be maintained with
ticagrelor because of rapid onset ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
4. Ticagrelor
4. Ticagrelor therapy may be resumed immediately after
needle placement/catheter removal, provided a loading
dose of the drugs is not administered. If a loading dose is
administered, we suggest a time interval of 6 hrs between
catheter removal and administration ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
4. Ticagrelor
4. Ticagrelor therapy may be resumed immediately after
needle placement/catheter removal, provided a loading
dose of the drugs is not administered. If a loading dose is
administered, we suggest a time interval of 6 hrs between
catheter removal and administration ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
5. Platelet GPIIb/IIIa Receptor Antagonists
1. Preop : We recommend that neuraxial techniques should
be avoided until platelet function – as impacted by the
GPIIb/IIIa inhibitor - has recovered. ( Pts are typically on dual
therapy and may still have residual NSAIDs effect )
No change
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
5. Platelet GPIIb/IIIa Receptor Antagonists
2. Postop : Although GPIIb/IIIa antagonists are
contraindicated within 4 weeks of surgery, should one be
emergently administered in postop period (following
neuraxial technique), we recommend infusion be limited to
drugs minimizing sensory and motor block to facilitates
assessment of neuro function and pt be monitored
neurologically ( grade1C ). Timing of catheter removal is
based on ongoing risk of thromboembolism and need for
continued antithrombotic therapy and potential for spinal
bleeding during catheter maintenance and removal
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
6. Cilastozol
1. Based on elimination half life, we suggest that neuraxial
techniques be avoided for 2 days after discontinuation of
cilastozol ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
6. Cilastozol
2. We suggest that neuraxial catheters be removed prior to
reinstitution of cilastazol therapy postoperatively ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
6. Cilastozol
3. We suggest that the first postop dose of cilastazol for
administered 6 hrs after neuraxial catheter removal
( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
7. Dipyridamol
1. Based on elimination half life, we suggest discontinuing
extended release dipyridamol for 24 hrs prior to neuraxial
block. Aspirin may be continued perioperatively ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
7. Dipyridamol
2. We suggest that neuraxial catheters be removed prior to
reinstitution of dipyridamol therapy postoperatively
( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
7. Dipyridamol
3. We suggest that first postop dose of dipyridamol be
administered 6 hrs after neuraxial catheter removal
( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
8. Cangrelor
1. Based on elimination half life, we suggest neuraxial
techniques be avoided for 3 hrs after discontinuation of
cangrelor ( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
8. Cangrelor
2. We suggest that neuraxial catheters be removed prior to
reinstitution of cangrelor therapy postoperatively( grade 2C )
NEW
13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS
8. Cangrelor
3. We suggest that the first postop dose of cangrelor be
administered 8 hrs after neuraxial catheter removal
( grade 2C )
NEW
14. Anesthetic Mx of pt receiving HERBAL MEDICATIONS
1. The use of herbal medications does not create a level of risk
that will interfere with the performance of neuraxial block.
We recommend against the mandatory discontinuation of
these medications or avoidance of regional anesthetic
techniques in patients in whom these medications have
been administered ( grade1C )
No change
15. Anesthetic Mx of ANTICOAGULATED PARTURIENT
1. Given the limited pharmacological data on antithrombotic
agents in pregnancy and in the absence of a large series of
neuraxial techniques in the pregnant population receiving
prophylaxis or treatment for VTE, we suggest that the ASRA
guidelines be applied to parturients ( grade2C )
No change
15. Anesthetic Mx of ANTICOAGULATED PARTURIENT
2. However, in circumstances involving select high-risk
parturients receiving VTE prophylaxis and requiring urgent
interventions for maternal or fetal indications, the risk of
general anesthesia may be greater than neuraxial
anesthesia, and exceptions/modifications of the ASRA
guidelines may be appropriate ( grade2C )
NEW
16. Anesthetic Mx of pt undergoing PLEXUS/PERIPHERAL
BLOCK
1. For pts undergoing perineuraxial , deep plexus or deep
peripheral block, we recommend that guidelines regarding
neuraxial techniques be similarly applied ( grade 1C )
No change
16. Anesthetic Mx of pt undergoing PLEXUS/PERIPHERAL
BLOCK
2. For pts undergoing other plexus or peripheral techniques, we
suggest management ( performance, catheter maintenance
and removal ) based on site compressibility, vascularity and
consequences of bleeding , should it occur ( grade 2C )
NEW
THANK YOU
DR KRUNAL BHATT
No Change

More Related Content

What's hot

Failed spinal-anesthesia-mgmc
Failed spinal-anesthesia-mgmcFailed spinal-anesthesia-mgmc
Failed spinal-anesthesia-mgmcHarith Daggupati
 
Ischemic heart disease and anesthetic management
Ischemic heart disease and anesthetic managementIschemic heart disease and anesthetic management
Ischemic heart disease and anesthetic managementkrishna dhakal
 
Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction Arun Shetty
 
Interscalene & supraclavicular nerve blocks
Interscalene  & supraclavicular nerve blocksInterscalene  & supraclavicular nerve blocks
Interscalene & supraclavicular nerve blocksDavis Kurian
 
Anaesthesia for neurosurgery
Anaesthesia for neurosurgeryAnaesthesia for neurosurgery
Anaesthesia for neurosurgerySiti Azila
 
Thoracic anaesthesia
Thoracic anaesthesiaThoracic anaesthesia
Thoracic anaesthesiaAnkit Gajjar
 
Rapid sequence spinal anesthesia (RSS).pptx
Rapid sequence spinal anesthesia (RSS).pptxRapid sequence spinal anesthesia (RSS).pptx
Rapid sequence spinal anesthesia (RSS).pptxgauthampatel
 
Copd and anaesthetic management
Copd and anaesthetic managementCopd and anaesthetic management
Copd and anaesthetic managementKanika Chaudhary
 
Lower limb blocks
Lower limb blocksLower limb blocks
Lower limb blocksgaganbrar18
 
Neuromuscular Monitoring
Neuromuscular MonitoringNeuromuscular Monitoring
Neuromuscular MonitoringMohtasib Madaoo
 
Extubation protocol in the OR and ICU
Extubation protocol in the OR and ICUExtubation protocol in the OR and ICU
Extubation protocol in the OR and ICURalekeOkoye
 
Airway local blocks
Airway local blocksAirway local blocks
Airway local blocksNisar Arain
 
Anaesthesia for cardiac patient undergoing non cardiac surgery
Anaesthesia for cardiac patient undergoing non cardiac surgeryAnaesthesia for cardiac patient undergoing non cardiac surgery
Anaesthesia for cardiac patient undergoing non cardiac surgeryDhritiman Chakrabarti
 
Magnesium sulphate and anesthesiologist
Magnesium sulphate and anesthesiologistMagnesium sulphate and anesthesiologist
Magnesium sulphate and anesthesiologistdr tushar chokshi
 
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmatic
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmaticAnaesthetic management of tracheoesophageal fistula and congenital diaphragmatic
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmaticIqraa Khanum
 
Anaesthesia for posterior fossa surgery
Anaesthesia for posterior fossa surgeryAnaesthesia for posterior fossa surgery
Anaesthesia for posterior fossa surgeryDhritiman Chakrabarti
 

What's hot (20)

Caudal anesthesia
Caudal anesthesiaCaudal anesthesia
Caudal anesthesia
 
Failed spinal-anesthesia-mgmc
Failed spinal-anesthesia-mgmcFailed spinal-anesthesia-mgmc
Failed spinal-anesthesia-mgmc
 
Ischemic heart disease and anesthetic management
Ischemic heart disease and anesthetic managementIschemic heart disease and anesthetic management
Ischemic heart disease and anesthetic management
 
Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction
 
Interscalene & supraclavicular nerve blocks
Interscalene  & supraclavicular nerve blocksInterscalene  & supraclavicular nerve blocks
Interscalene & supraclavicular nerve blocks
 
Anaesthesia for neurosurgery
Anaesthesia for neurosurgeryAnaesthesia for neurosurgery
Anaesthesia for neurosurgery
 
Thoracic anaesthesia
Thoracic anaesthesiaThoracic anaesthesia
Thoracic anaesthesia
 
Rapid sequence spinal anesthesia (RSS).pptx
Rapid sequence spinal anesthesia (RSS).pptxRapid sequence spinal anesthesia (RSS).pptx
Rapid sequence spinal anesthesia (RSS).pptx
 
Copd and anaesthetic management
Copd and anaesthetic managementCopd and anaesthetic management
Copd and anaesthetic management
 
Lower limb blocks
Lower limb blocksLower limb blocks
Lower limb blocks
 
Neuromuscular Monitoring
Neuromuscular MonitoringNeuromuscular Monitoring
Neuromuscular Monitoring
 
Extubation protocol in the OR and ICU
Extubation protocol in the OR and ICUExtubation protocol in the OR and ICU
Extubation protocol in the OR and ICU
 
Awake intubation
Awake intubationAwake intubation
Awake intubation
 
Airway local blocks
Airway local blocksAirway local blocks
Airway local blocks
 
Anaesthesia for cardiac patient undergoing non cardiac surgery
Anaesthesia for cardiac patient undergoing non cardiac surgeryAnaesthesia for cardiac patient undergoing non cardiac surgery
Anaesthesia for cardiac patient undergoing non cardiac surgery
 
Magnesium sulphate and anesthesiologist
Magnesium sulphate and anesthesiologistMagnesium sulphate and anesthesiologist
Magnesium sulphate and anesthesiologist
 
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmatic
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmaticAnaesthetic management of tracheoesophageal fistula and congenital diaphragmatic
Anaesthetic management of tracheoesophageal fistula and congenital diaphragmatic
 
Anaesthesia for posterior fossa surgery
Anaesthesia for posterior fossa surgeryAnaesthesia for posterior fossa surgery
Anaesthesia for posterior fossa surgery
 
NON OPERATING ROOM ANAESTHESIA
NON OPERATING ROOM ANAESTHESIANON OPERATING ROOM ANAESTHESIA
NON OPERATING ROOM ANAESTHESIA
 
Geriatric anaesthesia
Geriatric anaesthesiaGeriatric anaesthesia
Geriatric anaesthesia
 

Similar to ASRA Guidelines 4th Edition

ESA- antitrombotic therapy
ESA- antitrombotic therapyESA- antitrombotic therapy
ESA- antitrombotic therapyHelga Komen
 
Perioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyPerioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyGhaleb Almekhlafi
 
final presentation of anticoagulants.pptx
final presentation of anticoagulants.pptxfinal presentation of anticoagulants.pptx
final presentation of anticoagulants.pptxSwastika Swaro
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsNavin Jain‬
 
Current status of stroke intervention
Current status of stroke interventionCurrent status of stroke intervention
Current status of stroke interventionNeurologyKota
 
Anticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesiaAnticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesialogon2kingofkings
 
Journal Club Thrombolysis.pptx
Journal Club Thrombolysis.pptxJournal Club Thrombolysis.pptx
Journal Club Thrombolysis.pptxJatinJain869927
 
Neuraxial anesthesia and
Neuraxial anesthesia andNeuraxial anesthesia and
Neuraxial anesthesia andHossam atef
 
Anaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaestHSNZ
 
Management of acute stroke
Management of acute strokeManagement of acute stroke
Management of acute strokeSudhir Kumar
 
Dvt prophylaxis in icu
Dvt prophylaxis in icuDvt prophylaxis in icu
Dvt prophylaxis in icuHany Faisal
 
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017Alexandria University, Egypt
 
Total intravenous anesthesia (TIVA)
Total intravenous anesthesia (TIVA)Total intravenous anesthesia (TIVA)
Total intravenous anesthesia (TIVA)khamees aljazarah
 
Body ct protocols
Body ct protocolsBody ct protocols
Body ct protocolsbongsung
 

Similar to ASRA Guidelines 4th Edition (20)

ESA- antitrombotic therapy
ESA- antitrombotic therapyESA- antitrombotic therapy
ESA- antitrombotic therapy
 
Perioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyPerioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapy
 
final presentation of anticoagulants.pptx
final presentation of anticoagulants.pptxfinal presentation of anticoagulants.pptx
final presentation of anticoagulants.pptx
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulants
 
Current status of stroke intervention
Current status of stroke interventionCurrent status of stroke intervention
Current status of stroke intervention
 
final drugs (2).pptx
final drugs  (2).pptxfinal drugs  (2).pptx
final drugs (2).pptx
 
Good slide dvt
Good slide dvtGood slide dvt
Good slide dvt
 
Anticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesiaAnticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesia
 
Journal Club Thrombolysis.pptx
Journal Club Thrombolysis.pptxJournal Club Thrombolysis.pptx
Journal Club Thrombolysis.pptx
 
Neuraxial anesthesia and
Neuraxial anesthesia andNeuraxial anesthesia and
Neuraxial anesthesia and
 
Anaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulant
 
Vte prophylaxis
Vte prophylaxisVte prophylaxis
Vte prophylaxis
 
Management of acute stroke
Management of acute strokeManagement of acute stroke
Management of acute stroke
 
Dvt prophylaxis in icu
Dvt prophylaxis in icuDvt prophylaxis in icu
Dvt prophylaxis in icu
 
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017
Samir rafla noacs-a patient planned for intervention or surgery-cardioalex 2017
 
Total intravenous anesthesia (TIVA)
Total intravenous anesthesia (TIVA)Total intravenous anesthesia (TIVA)
Total intravenous anesthesia (TIVA)
 
Body ct protocols
Body ct protocolsBody ct protocols
Body ct protocols
 
Stroke guidelines 2018.pptx
Stroke guidelines 2018.pptxStroke guidelines 2018.pptx
Stroke guidelines 2018.pptx
 
Myo.infarction
Myo.infarctionMyo.infarction
Myo.infarction
 
Summary universal c
Summary universal cSummary universal c
Summary universal c
 

Recently uploaded

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 

Recently uploaded (20)

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 

ASRA Guidelines 4th Edition

  • 1. ASRA GUIDELINES 4th Edition, April 2018 ( 3RD Edition, Jan 2010 ) Dr Krunal Bhatt Anesthesiology and Critical Care AFMC, Pune
  • 2. • 1st consensus conference : 1997 • 2nd consensus conference : 2002 No Change
  • 3. LEVEL OF EVIDENCE • A : RCT and Meta Analysis • B : Observational and Epidemiological Series • C : Case Reports or Expert Opinion No Change
  • 4. GRADE OF RECOMMENDATION • 1 : General Agreement in the efficacy • 2 : Conflicting Evidence or opinion on usefulness • 3 : May not be useful • We recommend : grades 1A,1B,1C • We suggest : grades 2A,2B,2C No Change
  • 5. CONCERNS 1. Administration of thromboprophylaxis 2. Anesthetic Mx of pt receiving Thrombolytic Therapy 3. Anesthetic Mx of pt receiving UFH 4. Anesthetic Mx of pt receiving LMWH 5. Anesthetic Mx of pt receiving Fondaparinaux 6. Anesthetic Mx of pt receiving Rivaroxaban 7. Anesthetic Mx of pt receiving Apixaban 8. Anesthetic Mx of pt receiving Edoxaban 9. Anesthetic Mx of pt receiving Betrixaban 10. Anesthetic Mx of pt receiving Direct Thrombin Inhibitors
  • 6. 11. Anesthetic Mx of pt receiving Dabigatran 12. Regional Anesthetic Mx of pt receiving Warfarin 13. Anesthetic Mx of pt receiving Antiplatelet Medications 14. Anesthetic Mx of pt receiving Herbal Therapy 15. Anesthetic Mx of the Anticoagulated Parturient 16. Anesthetic Mx of pt receiving undergoing Plexus or Peripheral Block
  • 7. VTE RISK FACTORS FOR VTE Surgery Trauma Immobility Cancer and its treatment Venous compression H/o VTE Increasing age Acute medical illness Estrogen pills/HRT Inherited/Acquired Thrombophilia Erythropoiesis modulating agents Pregnancy and Post partum period IBDz Nephrotic syndrome Myeloproliferative dz PNH Obesity CVC SERM
  • 8. 1. Administration of THROMBOPROPHYLAXIS 1. For each of the antithrombotic agents, we recommend that clinicians follow FDA approved dosing and ACCP Mx guidelines ( grade 1A ) No Change
  • 9. 2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY 1. In patients scheduled to receive thrombolytic therapy, we recommend that the pt be queried and medical record reviewed for a recent history of lumbar puncture, spinal or epidural anesthesia, or ESI to allow appropriate monitoring guidelines detailing original contraindications to thrombolytic drugs suggest avoidance of these drugs for 10 days following puncture of non compressible vessels ( grade 1A ) No Change
  • 10. 2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY 2. In patients who have received fibrinolytic and thrombolytic drugs, we recommend against performance of spinal or epidural anesthetics except in highly unusual circumstances ( grade 1A ) No Change
  • 11. 2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY 3. Data are not available to clearly outline the length of time neuraxial puncture should be avoided after discontinuation of these drugs. However, a 48 hr time interval and documentation of normalization of clotting studies ( including fibrinogen ) are suggested ( grade 2C ) No Change
  • 12. 2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY 4. In those patients who have received neuraxial blocks at or near the time of fibrinolytic and thrombolytic therapy, we recommend that neurological monitoring should be continued for an appropriate interval. It may be that the interval of monitoring should not be more than 2 hrs between neurological checks. If neuraxial blocks have been combined with fibrinolytic and thrombolytic therapy and ongoing epidural catheter infusion, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function ( grade 1C ) No Change
  • 13. 2. Anesthetic Mx of pt receiving THROMBOLYTIC THERAPY 5. There is no definitive recommendation for removal of neuraxial catheters in pts who unexpectedly receive fibrinolytic and thrombolytic therapy during a neuraxial catheter infusion. We suggest the measurement of fibrinogen level ( one of that last clotting factors to recover ) to evaluate the presence of residual thrombolytic effect and appropriate timing of catheter removal ( grade 2C ) No Change
  • 14. IV and SC UFH
  • 15. 3. Anesthetic Mx of pt receiving UFH 1. We recommend daily review of the pt’s medical record to determine the concurrent use of medications that affect other components of the clotting mechanisms. These medications include antiplatelet medications, LMWH, and oral anticoagulants ( grade 1B ) No Change
  • 16. 3. Anesthetic Mx of pt receiving UFH 2. Since HIT may occur during heparin administration, we recommend that pt receiving IV or SC UFH for more than 4 days have a platelet count assessed prior to neuraxial block or catheter removal ( grade 1C ) No Change
  • 17. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 1. Discontinue heparin infusion 4 to 6 hrs and verify normal coagulation status prior to neuraxial blockade ( grade 1A ) No Change
  • 18. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 2. Avoid neruaxial techniques in pts with other coagulopathies ( grade 1A ) No Change
  • 19. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 3. Delay heparin administration for 1 hr after needle placement ( grade 1A ) No Change
  • 20. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 4. Remove indwelling neuraxial catheters 4 to 6 hrs after the last heparin dose ( and after assessment of the pt’s coagualtion status ) ; reheparinize 1 hr after catheter removal ( grade 1A ) No Change
  • 21. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 5. Monitor pt postoperatively to provide early detection of motor blockade and consider use of minimal concentration of LAs to enhance early detection of spinal hematoma ( grade 1A ) No Change
  • 22. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 6. Although the occurrence of bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk benefit decision about proceeding in each case are warranted ( grade 1A ) No Change
  • 23. 3. Anesthetic Mx of pt receiving UFH 3. Intravenous Heparin 7. Currently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anticoagulation of cardiac surgery. We suggest postop monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits ( grade 2C ) No Change
  • 24. 3. Anesthetic Mx of pt receiving UFH 4. Subcutaneous Heparin 1. Preop low dose UFH for thromboprophylaxis. We suggest, in pts receiving SC low dose UFH with dosing regimens of 5000 IU BID/TID, neuraxial block occur 4 to 6 hrs after heparin administration, or coagulation status be assessed ( grade 2C ) No Change
  • 25. 3. Anesthetic Mx of pt receiving UFH 4. Subcutaneous Heparin 2. Preop “higher dose” UFH for thromboprophylaxis (eg. Individual heparin dose of 7500-10000 IU BID or daily dose of ≤ 20000 IU ). We suggest, neuraxial block occur 12 hrs after SC heparin administration and assessment of coagulation status ( grade 2C ) No Change
  • 26. 3. Anesthetic Mx of pt receiving UFH 4. Subcutaneous Heparin 3. Preop therapeutic UFH ( eg. Individual dose > 10000 IU SC per dose or > 20000 IU total daily dose ). We suggest neuraxial block occure 24 hrs after SC heparin administration and assessment of coagulation status ( grade 2C ) No Change
  • 27. 3. Anesthetic Mx of pt receiving UFH 4. Subcutaneous Heparin 4. Postop low dose UFH. There is no contraindication to maintaining neuraxial catheters in the presence of low dose UFH. We suggest catheter removal occur 4 to 6 hrs after heparin administration. Subsequent heparin administration may occur 1 hr after catheter removal ( grade 2C ) No Change
  • 28. 3. Anesthetic Mx of pt receiving UFH 4. Subcutaneous Heparin 5. Postop “Higher dose” UFH. The safety of indwelling neuraxial catheters in pts receiving doses > 5000 IU or > 15000 IU of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodefits ( eg. Enhanced neuro monitoring occur and neuraxial solutions to minimize sensory and motor block ) be applied ( grade 2C ) No Change
  • 29. LMWH
  • 30. 4. Anesthetic Mx of pt receiving LMWH 1. The anti-factor Xa level is not predictive of the risk of bleeding, although it may be useful in monitoring efficacy of therapy with therapeutic ( high dose ) regimens. We recommend against the routine use of monitoring of anti- factor Xa level. An acceptable level of residual anti-factor Xa level for performance of neuraxial block remains undetermined ( grade 1A ) The increased availability of anti-factorXa activity level allows for preop assessment of residual anticoagualant effect in pt on higher dose LMWH
  • 31. 4. Anesthetic Mx of pt receiving LMWH 2. Antiplatelet or oral anticoagulant medications administered in combination with LMWH increase the risk of spinal hematoma. Education of entire pt care team is necessary to avoid potentiation of the anticoagualnt effects. We recommend against concomitant administration of medications affecting hemostatsis, such as antiplatelet drugs, standard heparin or dextran, regardless of LMWH dosing regimen when there is an indwelling neuraxial catheter ( grade 1A ) No Change
  • 32. 4. Anesthetic Mx of pt receiving LMWH 3. Since HIT may occur during LMWH administration, We recommend that pts receiving LMWH for greater than 4 days have a platelet count assessed prior to neuraxial block or catheter removal ( grade 1C ) No Change
  • 33. 4. Anesthetic Mx of pt receiving LMWH 4. The presence of blood during needle and catheter placement does not necessitate postponement of surgery. We suggest that initiation of LMWH therapy in this setting should be delayed for 24 hrs postop and that this consideration be discussed with the surgeon ( grade 2C ) No Change
  • 34. 4. Anesthetic Mx of pt receiving LMWH 5. Preop LMWH 1. We recommend that needle placement should occur at least 12 hrs after prophylactic LMWH dose ( grade 1C ) No Change
  • 35. 4. Anesthetic Mx of pt receiving LMWH 5. Preop LMWH 2. In pts administered a dose of LMWH 2 hrs preoperatively (general surgery pts), we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity ( grade 1A ) No Change
  • 36. 4. Anesthetic Mx of pt receiving LMWH 5. Preop LMWH 3. In pts receiving higher (therapeutic) LMWH (eg. Enoxaparin 1mg/kg 12hrly or 1.5mg/kg daily, Dalteparin 120U/kg 12hrly or 200U/kg daily, Tinzaparin 175U/kg daily), We recommend delay of ≥24hrs to needle/catheter placement (grade 1C). Consider checking anti-factorXa activity, particularly in elderly pts and with renal insufficiency. Acceptable level of residual anti-factorXa activity to proceed with neuraxial block remains undetermined (grade 2C) Residual anti-factorXa activity may be present even after 24hrs. Assessment, especially in pt with mod to severe renal insufficiency, may be considered.
  • 37. 4. Anesthetic Mx of pt receiving LMWH 6. Postop LMWH 1. BID prophylatic dose, associated with increased risk of spinal hematoma. We recommend 1st dose LMWH should be administered following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, & only in presence of adequate (surgical) hemostasis. Indwelling catheters be removed prior to initiation of LMWH thromboprophylaxis. Administration of LMWH be delayed for 4hr after catheter removal ( grade 1C ) Previously recommeded was a 1st dose 24hr after needle/catheter placement and delay of LMWH dosing for only 2hr after catheter removal. These recommendations incorporate labelling changes made by FDA.
  • 38. 4. Anesthetic Mx of pt receiving LMWH 6. Postop LMWH 2. OD prophylatic dose. We recommend 1st dose LMWH should be administered ≥12hrs after needle/catheter placement. The 2nd postop dose should occur >24hrs after 1st dose. Indwelling catheters don't represent increased risk and may be maintained. No additional hemostasis altering drugs be administered because of additive effects. Catheter removed 12hr last dose LMWH. Subsequent LMWH ≥4hrs after catheter removal ( grade 1C ) Previously recommended was 10-12hrs for both needle/catheter placement and catheter removal. Subsequent LMWH 2hrs after catheter removal. These recommendations incorporate labeling changes made by FDA.
  • 39. 4. Anesthetic Mx of pt receiving LMWH 6. Postop LMWH 3. OD/BD Therapeutic dose. Therapeutic dose LMWH may be resumed 24 after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery. We recommend that indwelling neuraxial catheter be removed 4 hrs prior to 1st postop dose and ≥ 24 hrs after needle/catheter placement, whichever is greater ( grade 1C ) No Change
  • 40. ANTI – FACTOR Xa AGENTS • Fondaparinux
  • 41. 5. Anesthetic Mx of pt receiving FONDAPARINAUX 1. Based on the sustained and irreversible antithrombotic effect, early postop dosing and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials ( single needle pass, atraumatic needle placement, avoidance of indwelling neuraxial catheters ). If this is not feasible, an alternate method of prophylaxis should be considered ( grade 1C ) No Change
  • 42. 5. Anesthetic Mx of pt receiving FONDAPARINAUX 2. We suggest that neuraxial catheters 6 hrs be removed prior to 1st postop dose ( grade 2C ) No Change
  • 43. NEW DIRECT ORAL ANTI-FACTOR Xa AGENTS • Rivaroxaban • Apixaban • Edoxaban • Betrixaban
  • 44. 6. Anesthetic Mx of pt receiving RIVAROXABAN 1. We suggest that rivaroxaban be discontinued 72 hrs prior to neuraxial block. Consider checking rivaroxaban or anti-factor Xa activity level if less than 72 hrs. An acceptable level of residual rivaroxaban activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 45. 6. Anesthetic Mx of pt receiving RIVAROXABAN 2. We suggest that neuraxial catheters be removed 6 hrs prior to the 1st postop dose ( grade 2C ) NEW
  • 46. 6. Anesthetic Mx of pt receiving RIVAROXABAN 3. With unanticipated administration with indwelling catheter, we suggest that rivaroxaban dosing be held for 22 to 26 hrs before or an anti-factor Xa assay calibrated to rivaroxaban be assessed before catheter is removed ( grade 2C ) NEW
  • 47. 7. Anesthetic Mx of pt receiving APIXABAN 1. We suggest that Apixaban be discontinued 72 hrs prior to neuraxial block. Consider checking Apixaban or anti-factor Xa activity level if less than 72 hrs. An acceptable level of residual Apixaban activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 48. 7. Anesthetic Mx of pt receiving APIXABAN 2. We suggest that neuraxial catheters be removed 6 hrs prior to the 1st postop dose ( grade 2C ) NEW
  • 49. 7. Anesthetic Mx of pt receiving APIXABAN 3. With unanticipated administration with indwelling catheter, we suggest that Apixaban dosing be held for 26 to 30 hrs before or an anti-factor Xa assay calibrated to Apixaban be assessed before catheter is removed ( grade 2C ) NEW
  • 50. 8. Anesthetic Mx of pt receiving EDOXABAN 1. We suggest that Edoxaban be discontinued 72 hrs prior to neuraxial block. Consider checking Edoxaban or anti-factor Xa activity level if less than 72 hrs. An acceptable level of residual Edoxaban activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 51. 8. Anesthetic Mx of pt receiving EDOXABAN 2. We suggest that neuraxial catheters be removed 6 hrs prior to the 1st postop dose ( grade 2C ) NEW
  • 52. 8. Anesthetic Mx of pt receiving EDOXABAN 3. With unanticipated administration with indwelling catheter, we suggest that Edoxaban dosing be held for 20 to 28 hrs before or an anti-factor Xa assay calibrated to Edoxaban be assessed before catheter is removed ( grade 2C ) NEW
  • 53. 9. Anesthetic Mx of pt receiving BETRIXABAN 1. We suggest that Betrixaban be discontinued a minimum of 3 days prior to neuroaxial block. Consider checking Betrixaban or anti-factor Xa activity level if less than 3 days ( grade 2C ) NEW
  • 54. 9. Anesthetic Mx of pt receiving BETRIXABAN 2. We suggest against the performance of neuraxial blocks in pt with a CrCL < 30ml/min ( grade 2C ) NEW
  • 55. 9. Anesthetic Mx of pt receiving BETRIXABAN 3. We suggest that neuraxial catheters 5 hrs be removed prior to next dose ( grade 2C ) NEW
  • 56. 9. Anesthetic Mx of pt receiving BETRIXABAN 4. With unanticipated administration with indwelling catheter, we suggest that Betrixaban dosing be held for 72 hrs, than the catheter removed ( grade 2C ) NEW
  • 57. DIRECT THROMBIN INHIBITORS • Desirudin • Bivalirudin • Argatroban
  • 58. 10. Anesthetic Mx of pt receiving Parenteral DTI 1. In pt receiving parenteral thrombin inhibitors, we recommend against the performance of neuraxial techniques ( grade 2C ) No Change
  • 60. 11. Anesthetic Mx of pt receiving DABIGATRAN 1. We suggest that Dabigatran be discontinued 120 hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding ( eg. Age>65yrs, hypertension, concomitant antiplatelet medications ) , a more graded approach may be considered NEW
  • 61. 11. Anesthetic Mx of pt receiving DABIGATRAN 1. We suggest that Dabigatran be discontinued 120 hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding ( eg. Age>65yrs, hypertension, concomitant antiplatelet medications ) , a more graded approach may be considered 1. We suggest dabigatran be discontinued 72hrs in pt with CrCL ≥80ml/min. Consider checking dTT or ECT if <72hrs. Acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 62. 11. Anesthetic Mx of pt receiving DABIGATRAN 1. We suggest that Dabigatran be discontinued 120 hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding ( eg. Age>65yrs, hypertension, concomitant antiplatelet medications ) , a more graded approach may be considered 2. We suggest dabigatran be discontinued 96hrs in pt with CrCL 50-79ml/min. Consider checking dTT or ECT if <96hrs. Acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 63. 11. Anesthetic Mx of pt receiving DABIGATRAN 1. We suggest that Dabigatran be discontinued 120 hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding ( eg. Age>65yrs, hypertension, concomitant antiplatelet medications ) , a more graded approach may be considered 3. We suggest dabigatran be discontinued 120hrs in pt with CrCL 30-49ml/min. Consider checking dTT or ECT if <120hrs. Acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined ( grade 2C ) NEW
  • 64. 11. Anesthetic Mx of pt receiving DABIGATRAN 1. We suggest that Dabigatran be discontinued 120 hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding ( eg. Age>65yrs, hypertension, concomitant antiplatelet medications ) , a more graded approach may be considered 4. We suggest against the performance of neuraxial blocks in pts with CrCL <30ml/min ( grade 2C ) NEW
  • 65. 11. Anesthetic Mx of pt receiving DABIGATRAN 2. We suggest that neuraxial catheters be removed 6 hrs prior to the 1st postop dose ( grade 2C ) NEW
  • 66. 11. Anesthetic Mx of pt receiving DABIGATRAN 3. With unanticipated administration with indwelling catheter, we suggest that dabigatran dosing be held for 34 to 36 hrs before or dTT or ECT assessed before the catheter is removed ( grade 2C ) NEW
  • 67. 12. Regional Anesthetic Management of pt on WARFARIN 1. Caution should be used when performing neuraxial tech in pts recently discontinued from chronic warfarin therapy. In first 1-3 days after discontinuation of warfarin therapy, coagulation status (reflected primarily by factor II and X levels) may not be adequate for hemostasis despite a decrease in INR (Indicating return of factor VII activity). Adequate levels of factor II,VII,IX and X may not be present until INR is within normal limits. We recommend the anticoagulant therapy must be stopped (Ideally 5 days prior to planned procedure), and the INR normalized prior to initiation of neuraxial block ( grade 1B ) No Change
  • 68. 12. Regional Anesthetic Management of pt on WARFARIN 2. We recommend against the concurrent use of medications that affect other component of the clotting mechanisms and may increase the risk of bleeding complications for patients receiving oral anticoagulants and do so without influencing the INR. These medications include aspirin and other NSAIDs, thienopyridines, UFH and LMWH ( grade 1A ) No Change
  • 69. 12. Regional Anesthetic Management of pt on WARFARIN 3. In pt who are likely to have an enhanced response to drug, we recommend that reduced dose be administered ( grade 1B ) No Change
  • 70. 12. Regional Anesthetic Management of pt on WARFARIN 4. In pts receiving an initial dose of warfarin prior to surgery, we suggest INR should be checked prior to neuraxial block if the first dose was given > 24hrs earlier or a second dose of oral anticoagulant has been administered ( grade 2C ) No Change
  • 71. 12. Regional Anesthetic Management of pt on WARFARIN 5. In pts receiving low dose of warfarin therapy during epidural analgesia, we suggest that their INR be monitored on a daily basis ( grade 2C ) No Change
  • 72. 12. Regional Anesthetic Management of pt on WARFARIN 6. Neurological monitoring of sensory and motor function should be performed routinely during epidural analgesia for pt on warfarin therapy. To facilitate , we recommend that the type of analgesic solution be tailored to minimize degree of sensory and motor blockade ( grade 1C ) No Change
  • 73. 12. Regional Anesthetic Management of pt on WARFARIN 7. As thromboprophylaxis with warfarin is initiated, we suggest that neuraxial catheters be removed when the INR <1.5. While removal of epidural catheters 12-24hrs after warfarin was given does not appear to represent increase risk, the risk of removing epidural catheter at 48hrs is not guaranteed. This is a new recommendation based on recent lab studies assessing factor levels and INR as well as clinical studies in pts receiving wararin during epidural catheterization
  • 74. 12. Regional Anesthetic Management of pt on WARFARIN 8. In pt with INR >1.5 but <3, the increase in risk with progressive INR prolongation remains unknown. We suggest indwelling catheters may be maintained with caution, based on INR and duration of warfarin therapy ( grade 2C ) This is a new recommendation based on recent lab studies assessing factor levels and INR as well as clinical studies in pts receiving wararin during epidural catheterization
  • 75. 12. Regional Anesthetic Management of pt on WARFARIN 9. In pt with INR >3 , we recommend that the warfarin dose be held or reduced in pts with indwelling neuraxial catheters ( grade1A ) We can make no definitive recommendation regarding the management to facilitate removal of neuraxial catheters in pt with therapeutic levels of anticoagulation during neuraxial catheter infusion ( grade 2C ) No Change
  • 76. 12. Regional Anesthetic Management of pt on WARFARIN 10. We suggest that neurological assessment be continued for at least 24 hrs following catheter removal ( grade 2C ) No Change
  • 77. ANTIPLATELET MEDICATIONS • NSAIDs • Thienopyridines • Ticagrelor • Cangrelor • Pl GPIIb/IIIa Receptor Antagonists • Cilastazol • Dipyridamol
  • 78. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 1. NSAIDs 1. NSAIDs appear to represent no added significant risk of development of spinal hematoma in pt having epidural or spinal anesthesia. NSAIDs ( including Aspirin ) do not create a level of risk that will interfere with the performance of neuraxial blocks. In pts receiving these medications, we do not identify specific concerns as to the timing of single injection or catheter techniques in relationship to the dosing of NSAIDs, postop monitoring, or the timing of neuraxial catheter removal ( grade 1A ) No Change
  • 79. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 1. NSAIDs 2. In pts receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other (nonNSAIDs) antiplatelet agents, oral anticoagulants, UFH & LMWH is anticipated in early postop period because of increase risk of bleeding complications. COX2 inhibitors have minimal effect on platelet function and should be considered in pt who require anti-inflammatory therapy in presence of anticoagulation ( grade 2C ) No Change
  • 80. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 2. Thienopyridines 1. Preop : Based on labelling and surgical/procedural experience, the recommended time interval between discontinuation of thienopyridine therapy and neuraxial blockade is 10 days for ticlopidine, 5-7 days for clopidogrel, and 7-10 days for prasugrel ( grade 1C ) Previous time intervals were 14days for ticlopidine and 7 days for clopidogrel. The new time intervals reflect ACCP recommendations. The prasugrel recommendation is new.
  • 81. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 2. Thienopyridines 2. Postop : In accordance with ACCP recommendations, thienopyridine therapy may be reinstituted 24 hrs postoperatively ( grade 1A ) NEW
  • 82. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 2. Thienopyridines 3. Neuraxial catheters should not be maintained with prasugrel or ticagrelor because of rapid onset. However, because the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1-2 days, provided a loading dose of the antiplatelet agent is not administered. ( grade 1A ) NEW
  • 83. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 2. Thienopyridines 4. Thienopyridine therapy may be resumed immediately after needle placement/catheter removal, provided a loading dose of the drugs is not administered. If a loading dose is administered, we suggest a time interval of 6 hrs between catheter removal and administration ( grade 2C ) NEW
  • 84. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 3. ASRA SOCIETY FORGET TO MENTION THIS POINT. I HAVE MAILED THEM REGARDING THIS.
  • 85. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 4. Ticagrelor 1. Preop : Based on labeling and surgical/procedural experience, the recommended time interval between discontinuation of ticagrelor therapy and neuraxial blockade is 5-7 days ( grade 1C ) NEW
  • 86. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 4. Ticagrelor 2. Postop : In accordance with ACCP recommendations, ticagrelor therapy may be reinstituted 24 hrs postoperatively ( grade 1A ) NEW
  • 87. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 4. Ticagrelor 3. Neuraxial catheters should not be maintained with ticagrelor because of rapid onset ( grade 2C ) NEW
  • 88. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 4. Ticagrelor 4. Ticagrelor therapy may be resumed immediately after needle placement/catheter removal, provided a loading dose of the drugs is not administered. If a loading dose is administered, we suggest a time interval of 6 hrs between catheter removal and administration ( grade 2C ) NEW
  • 89. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 4. Ticagrelor 4. Ticagrelor therapy may be resumed immediately after needle placement/catheter removal, provided a loading dose of the drugs is not administered. If a loading dose is administered, we suggest a time interval of 6 hrs between catheter removal and administration ( grade 2C ) NEW
  • 90. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 5. Platelet GPIIb/IIIa Receptor Antagonists 1. Preop : We recommend that neuraxial techniques should be avoided until platelet function – as impacted by the GPIIb/IIIa inhibitor - has recovered. ( Pts are typically on dual therapy and may still have residual NSAIDs effect ) No change
  • 91. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 5. Platelet GPIIb/IIIa Receptor Antagonists 2. Postop : Although GPIIb/IIIa antagonists are contraindicated within 4 weeks of surgery, should one be emergently administered in postop period (following neuraxial technique), we recommend infusion be limited to drugs minimizing sensory and motor block to facilitates assessment of neuro function and pt be monitored neurologically ( grade1C ). Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and potential for spinal bleeding during catheter maintenance and removal NEW
  • 92. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 6. Cilastozol 1. Based on elimination half life, we suggest that neuraxial techniques be avoided for 2 days after discontinuation of cilastozol ( grade 2C ) NEW
  • 93. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 6. Cilastozol 2. We suggest that neuraxial catheters be removed prior to reinstitution of cilastazol therapy postoperatively ( grade 2C ) NEW
  • 94. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 6. Cilastozol 3. We suggest that the first postop dose of cilastazol for administered 6 hrs after neuraxial catheter removal ( grade 2C ) NEW
  • 95. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 7. Dipyridamol 1. Based on elimination half life, we suggest discontinuing extended release dipyridamol for 24 hrs prior to neuraxial block. Aspirin may be continued perioperatively ( grade 2C ) NEW
  • 96. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 7. Dipyridamol 2. We suggest that neuraxial catheters be removed prior to reinstitution of dipyridamol therapy postoperatively ( grade 2C ) NEW
  • 97. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 7. Dipyridamol 3. We suggest that first postop dose of dipyridamol be administered 6 hrs after neuraxial catheter removal ( grade 2C ) NEW
  • 98. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 8. Cangrelor 1. Based on elimination half life, we suggest neuraxial techniques be avoided for 3 hrs after discontinuation of cangrelor ( grade 2C ) NEW
  • 99. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 8. Cangrelor 2. We suggest that neuraxial catheters be removed prior to reinstitution of cangrelor therapy postoperatively( grade 2C ) NEW
  • 100. 13. Anesthetic Mx of pt receiving ANTIPLATELET MEDICATIONS 8. Cangrelor 3. We suggest that the first postop dose of cangrelor be administered 8 hrs after neuraxial catheter removal ( grade 2C ) NEW
  • 101. 14. Anesthetic Mx of pt receiving HERBAL MEDICATIONS 1. The use of herbal medications does not create a level of risk that will interfere with the performance of neuraxial block. We recommend against the mandatory discontinuation of these medications or avoidance of regional anesthetic techniques in patients in whom these medications have been administered ( grade1C ) No change
  • 102. 15. Anesthetic Mx of ANTICOAGULATED PARTURIENT 1. Given the limited pharmacological data on antithrombotic agents in pregnancy and in the absence of a large series of neuraxial techniques in the pregnant population receiving prophylaxis or treatment for VTE, we suggest that the ASRA guidelines be applied to parturients ( grade2C ) No change
  • 103. 15. Anesthetic Mx of ANTICOAGULATED PARTURIENT 2. However, in circumstances involving select high-risk parturients receiving VTE prophylaxis and requiring urgent interventions for maternal or fetal indications, the risk of general anesthesia may be greater than neuraxial anesthesia, and exceptions/modifications of the ASRA guidelines may be appropriate ( grade2C ) NEW
  • 104. 16. Anesthetic Mx of pt undergoing PLEXUS/PERIPHERAL BLOCK 1. For pts undergoing perineuraxial , deep plexus or deep peripheral block, we recommend that guidelines regarding neuraxial techniques be similarly applied ( grade 1C ) No change
  • 105. 16. Anesthetic Mx of pt undergoing PLEXUS/PERIPHERAL BLOCK 2. For pts undergoing other plexus or peripheral techniques, we suggest management ( performance, catheter maintenance and removal ) based on site compressibility, vascularity and consequences of bleeding , should it occur ( grade 2C ) NEW
  • 106. THANK YOU DR KRUNAL BHATT No Change